GSK’s vaccines group — including R&D — faces heavy job cuts in latest restructuring
GSK’s top executives stayed mum yesterday on the location and number of layoffs likely to occur as the pharma giant integrated their vaccine R&D ops with the pharma side of the business. But it’s clear now that the ax will fall hard on the European vaccine group, with 935 jobs on the chopping block in Belgium and many more rumored cuts under discussion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.